ITCH-AMP
Integrating Transborder Collaboration for Combating High-Resistance Bacteria with AI-Enhanced Modified Phages
Università del Piemonte Orientale, Novara, Italy
Precise Health SA, Sion, Swisserland
Adamastor Bioservices, Magenta, Italy
Embedded Files
Operation co-financed by the European Union, the European Regional Development Fund, the Italian State, the Revolving Fund, the Swiss Confederation and the Canton of Valais within the Interreg VI-A Italy–Switzerland Cooperation Programme
The challenge
The increasing spread of antibiotic-resistant infections (AMR) is a common and urgent challenge across the Italy–Switzerland cross-border region. In particular, chronic infections related to bacterial biofilms are becoming increasingly critical in both hospital and community settings, with significant public health, economic and social consequences. Conventional antibiotics are largely ineffective against biofilms, calling for novel therapeutic strategies.
The general objective of the project is to establish a cross-border biotechnological platform for the design, production and validation of phage-based and protein-based antibiofilm agents. The goal is to deliver innovative therapeutic solutions with strong translational potential, contributing to AMR mitigation and the growth of biotech innovation within the region.
The expected change is twofold: on one hand, enhancing the region’s capacity to generate health and biotech innovation; on the other, delivering practical and effective tools to treat infections currently resistant to traditional medicine.
Page updated
Report abuse